Ann: Quarterly Activity Report and Appendix 4C, page-3

As expected, little sales although developer kits continue to be purchased which is encouraging given the lack of events.

With R&D refund they have 6-7 quarters of cash, and potentially 9-10 months if their Labcon case is sucessful.

Personally i would rather seen them putting their differences aside and getting back to bizz - win win - and hopefully the mediation can accelerate that and lead in a fast resolution.

Good to see trials at customer sites which is new, and OEM talks progressing- but that all only matters if leads to contracts and hopeful something is announced before Xmas.

The ISO granting, from experience dealing in the life sciences space is actually quite positive (or needed) and especially now if BCT is going directly to customers and their sites, that will be seen as a positive.